Parsons B, et al. - In this post hoc pooled analysis, researchers pooled data from three placebo-controlled trials enrolling Japanese subjects with postherpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), and spinal cord injury (SCI) and assessed the efficacy of pregabalin for treating moderate or severe baseline neuropathic pain (NeP) in Japanese subjects. A significant reduction in pain scores from baseline to endpoint was observed in correlation to receiving pregabalin treatment in subjects with both moderate and severe baseline pain compared to receiving placebo. Pregabalin administration also led to significant improvements in mean sleep scores from baseline to endpoint compared with placebo in these subjects. The common adverse events of pregabalin were dizziness, somnolence, weight gain, and peripheral edema consistent with the known safety profile.